Abstract
Even the most advanced drug-eluting stents evoke unresolved issues, including chronic inflammation, late thrombosis, and neoatherosclerosis. This highlights the need for novel strategies that improve stent biocompatibility. Our studies show that apolipoprotein A-I (apoA-I) reduces in-stent restenosis and platelet activation, and enhances endothelialization. These findings have therapeutic implications for improving stent biocompatibility.
Original language | English |
---|---|
Pages (from-to) | 200-209 |
Number of pages | 10 |
Journal | JACC: Basic to Translational Science |
Volume | 3 |
Issue number | 2 |
DOIs | |
Publication status | Published or Issued - Apr 2018 |
Externally published | Yes |
Keywords
- apolipoprotein A-I
- endothelialization
- neointimal hyperplasia
- platelet activation
- stent biocompatibility
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine